FindTrial
Sign In

A clinical trial to see the effect of some Ayurvedic formulations in the form of local application(Bidalaka)in the treatment of Klinnavartma with reference to Blephritis.

A randomized controlled trial to study the efficacy of Yashtimadhuaadi lepa and combination of chloramphenicol (1.0%) + hydrocortisone(0.5%) eye ointment in the management of Klinnavartma with reference to Blepharitis. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/066996
Enrollment
50
Registered
2024-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H010- Blepharitis

Interventions

None listed

Sponsors

Sane Guruji Arogya Kendra
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients having clinical signs and symptoms of klinnavartma 2)Patients will be selected with no reference to gender, occupation, religion, socio-economic status and duration of illness

Exclusion criteria

Exclusion criteria: 1)Patients associated with psoriasis and any other skin disease around eye 2)Patients suffering from severe illness like DM, HIV, HbsAG 3)Patient suffering with complications of Blepharitis such as conjunctivitis, keratitis, trichiasis

Design outcomes

Primary

MeasureTime frame
symptoms like klinnata(wetess of eyelids ) strava (discharge from eyes) kandu (itching in eyes) nistoda (pricking pain) will be decreased and relief from blepharitisTimepoint: Follow up on 3rd and 7th day symptoms will be noted before and after treatment.—

Secondary

MeasureTime frame
decrease in severity , duration of symptomsTimepoint: 18 months—

Countries

India

Contacts

Public ContactPROF DR MRS NILAKSHI PRADHAN

Mams Sumatibhai Shah Ayurved Mahavidhyalaya, Hadapsar, Pune

drnspradhan@yahoo.com9423580963

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026